Corcept Therapeutics

Overview

Compare with Emergent BioSolutions, COLLEGIUM PHARMACEUTICAL, INC or Pacira BioSciences, Inc., or pick any stock.

• TickerCORT on Nasdaq¹
• Industrypharmaceutical industry¹
• HeadquartersMenlo Park¹
• Websitewww.corcept.com
• Incorporated inDE⁶
• Business address101 Redwood Shores Parkway, Redwood City, Ca 94065⁶
• Filer categoryLarge accelerated filer⁶
• Legal formCorporation⁴
• LEI529900EO9LUTFMZ7FF90⁴
• StatusActive⁴
• LEI statusLapsed (not renewed)⁴
• Registered addressc/o Cogency Global Inc., 850 New Burton Road, Suite 201, 19904 Dover, United States⁴
• Registered withDivision of Corporations, Department of State, 2896087⁴

See how the biggest companies compare on our leaderboards

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.³

Corporate structure

Corcept Therapeutics sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Corcept Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Inventory

Properties, in its own words

We lease 50,632 square feet of office space in Redwood City, California for our corporate facilities. In December 2025, we exercised an expansion option of this lease for additional office space of 40,884 square feet, which commenced during the first quarter of 2026. Our current lease expires in June 2030.

Item 2 of the 10-K filed Feb 24, 2026.¹⁷

The story

From Wikipedia’s article on Corcept Therapeutics, shared under CC BY-SA 4.0.⁷

Leadership

Who has led Corcept Therapeutics, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJoseph K. Belanoff Jan 19, 2006 to now¹⁸
• PresidentRoberto Wandenkolk Vieira Sep 3, 2026 to now¹⁹
• PresidentRobert L. Roe Jan 25, 2006 to Feb 1, 2013²⁰
• Chief financial officerAtabak Mokari Mar 3, 2021 to now²¹
• Chief financial officerGary Charles Robb Sep 12, 2011 to Apr 27, 2021²²
• Chief financial officerCaroline M. Loewy Dec 2, 2008 to Dec 2, 2008²³
• Chief financial officerFred Kurland Mar 6, 2006 to Mar 6, 2006²⁴

Timeline

1. Sep 23, 20268-K Executive or director change; Regulation FD disclosure⁵¹
2. Jul 29, 20268-K Results of operations; Regulation FD disclosure⁵²
3. Jun 17, 20268-K Other events⁵³
4. Jun 3, 20268-K Other events⁵⁴
5. May 28, 20268-K Executive or director change; Shareholder vote⁵⁵
6. Apr 30, 20268-K Results of operations; Regulation FD disclosure⁵⁶
7. Mar 25, 20268-K Other events⁵⁷
8. Feb 24, 20268-K Results of operations; Regulation FD disclosure⁵⁸
9. Feb 19, 20268-K Other events⁵⁹
10. Jan 22, 20268-K Other events⁶⁰
11. Dec 31, 20258-K Other events⁶¹
12. Nov 4, 20258-K Results of operations; Regulation FD disclosure⁶²
13. Jan 19, 2006New chief executive Joseph K. Belanoff becomes CEO¹⁸
14. Apr 14, 2004Went public Listed on NASDAQ¹
15. 1998Founded Founded¹

Calendar

Coming up

1. Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.16 a share, on Nov 4, 2025.⁶³

When it reported results

1. Jul 29, 2026Reported quarterly or annual results⁵²
2. Apr 30, 2026Reported quarterly or annual results⁵⁶
3. Feb 24, 2026Reported quarterly or annual results⁵⁸
4. Nov 4, 2025Reported quarterly or annual results⁶²
5. Jul 31, 2025Reported quarterly or annual results⁶⁴
6. May 5, 2025Reported quarterly or annual results⁶⁵
7. Feb 26, 2025Reported quarterly or annual results⁶⁶
8. Oct 30, 2024Reported quarterly or annual results⁶⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

663 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 47 major events, 381 insider forms, 28 large holders, 186 other. The latest 20:

1. Oct 5, 20264 EDGAR
2. Oct 5, 20264 EDGAR
3. Oct 5, 20264 EDGAR
4. Oct 5, 20264 EDGAR
5. Oct 5, 20263 EDGAR
6. Oct 1, 2026144 EDGAR
7. Sep 28, 20264 EDGAR
8. Sep 23, 20268-K EDGAR
9. Sep 18, 20264 EDGAR
10. Sep 18, 20264 EDGAR
11. Sep 16, 20264 EDGAR
12. Sep 16, 20264 EDGAR
13. Sep 15, 2026144 EDGAR
14. Sep 14, 2026144 EDGAR
15. Sep 3, 20264 EDGAR
16. Sep 3, 20264 EDGAR
17. Sep 3, 20264 EDGAR
18. Sep 3, 20264 EDGAR
19. Sep 3, 20264 EDGAR
20. Sep 3, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

205 open-market trades by officers, directors and large owners since October 2021: 1 buys and 204 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• RENAISSANCE TECHNOLOGIES LLCSCHEDULE 13G/A, 5 filings Feb 11, 2022 to Aug 13, 2026⁶⁸
• INGALLS & SNYDER LLCSCHEDULE 13G/A, 5 filings Feb 4, 2022 to Apr 21, 2026⁶⁹
• VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 9, 2022 to Mar 26, 2026⁷⁰
• BlackRockSCHEDULE 13G/A, 6 filings Jan 28, 2022 to Jul 17, 2025⁷¹
• Joseph K. BelanoffSCHEDULE 13G/A, 4 filings Feb 11, 2022 to Feb 14, 2025⁷²
• G. Leonard Baker Jr.SC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 2024⁷³

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Corcept Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCORCEPT THERAPEUTICS INC²
• CIK0001088856
• Employer ID (EIN)77-0487658¹⁷
• Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company¹⁷
• Incorporated inDelaware¹⁷
• Fiscal year endsDecember 31²
• Industry code (SIC)2834 Pharmaceutical Preparations²
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance²
• Business address101 Redwood Shores Parkway, Redwood City, CA 94065²
• Phone650.688.8803²
• Shares outstanding108,098,397 as of Jul 22, 2026¹⁵
• Public float$6.1B as of Jun 30, 2025¹⁷
• AuditorErnst & Young LLP, San Mateo, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting¹⁷
• On EDGAR sinceDec 21, 2001²
• Filings2,043 in all: 4 (1,081), 8-K (241), 144 (143), SC 13G/A (92), 10-Q (68), 3 (53), 5 (35), 424B3 (30)²
  All 46 form types

  DEF 14A (23), SC 13G (23), 10-K (22), SC 13D/A (21), CORRESP (20), EFFECT (19), S-8 (19), UPLOAD (19), 4/A (18), CT ORDER (13), S-8 POS (11), POS AM (9), S-3 (9), S-1/A (8), SCHEDULE 13G/A (8), SC TO-I/A (7), S-1 (5), SC 13D (5), 3/A (4), 424B5 (3), ARS (3), D (3), REGDEX (3), S-3/A (3), 10-K/A (2), 424B2 (2), 424B4 (2), 424B7 (2), 8-K/A (2), DEFA14A (2), PRE 14A (2), SC TO-I (2), 10-Q/A (1), 144/A (1), 5/A (1), 8-A12G (1), REGDEX/A (1), RW (1)

• Latest filingsAnnual report (10-K) Feb 24, 2026
  Quarterly report (10-Q) Jul 29, 2026
  Proxy statement (DEF 14A) Apr 17, 2026
  Latest 8-K (8-K) Sep 23, 2026

Securities registered for trading

From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).¹⁷

Risk factors and legal proceedings

The risks Corcept Therapeutics names in Item 1A of its 10-K filed Feb 24, 2026: 29 risks under these headings, as written.¹⁷

• Risks Related to our Commercial Activities
• Risks Related to our Research and Development Activities
• Risks Related to our Intellectual Property
• Risks Related to our Stock
• General Risk Factors
• Failure to generate sufficient revenue from the sale of our Products would harm our financial results and would likely cause our stock price to decline.
• The availability of generic versions of Korlym could adversely affect our business, results of operations and financial position.
• Public perception of mifepristone or legislation limiting or barring its distribution or use for termination of early pregnancy may limit our ability to sell our current Products.
• New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for our Products, which would adversely affect our results of operations and financial position.
• We depend on vendors to manufacture the active pharmaceutical ingredient (“API”) and capsules or tablets for our commercialized products as well as our product candidates. We also depend on vendors to package our Products and dispense them to patients. If our vendors become unable or unwilling to perform these functions or are unable to meet demand for our Products and we cannot transfer these activities to other vendors in a timely manner, our business will be harmed.
• Other companies offer medications that treat patients with hypercortisolism by mechanisms different than Korlym’s. The availability of such competing treatments could limit our product revenue.
• Natural disasters, such as earthquakes, fires, extreme weather events or widespread outbreaks of a deadly disease, could disrupt our commercial and clinical activities or damage or destroy clinical trial sites, our office spaces, the residences of our employees or the facilities or residences of our vendors, contractors or consultants, which could significantly harm our operations.

Legal proceedings

Purported Securities Class Action

On February 20, 2026, a purported securities class action complaint was filed in the U.S. District Court for the Northern District of California by the Allegheny County Employees’ Retirement System (Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, et al., Case No. 3:26-cv-1525). The complaint names Corcept and certain of its executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges, among other things, that the defendants made or are responsible for making false and materially misleading statements and omissions regarding our NDA for our product candidate, relacorilant, as a treatment for patients with hypercortisolism. The complaint asserts a putative class period stemming from October 31, 2024, to December 30, 2025 and seeks damages, attorneys’ fees and costs and unspecified relief. We will vigorously defend ourselves against this lawsuit.

Teva Patent Litigation

In February 2018, we received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. (“Teva”) had submitted an Abbreviated New Drug Application (“ANDA”) to the FDA seeking authorization to manufacture and sell a generic version of Korlym prior to the expiration of patents related to Korlym that are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). In March 2018, we filed a lawsuit in the United States District Court for the District of New Jersey (“D.N.J.”) against Teva for infringement of our patents. In August 2020, Teva received final approval from the FDA for its ANDA in accordance with the Hatch-Waxman Act. And, in November 2020, the Patent Trial and Appeal Board (“PTAB”) issued a decision upholding the validity of U.S. Patent No. 10,195,214 (the “’214 patent”) in its entirety, which decision the Court of Appeals for the Federal Circuit upheld.

The opening of Item 3, Legal Proceedings.¹⁷

Links

• Websitewww.corcept.com¹
• X (Twitter)x.com/corcept¹
• Facebookwww.facebook.com/Corcept¹
• WikipediaCorcept Therapeutics
• WikidataQ15734041
• SEC EDGARCIK 1088856